To the best of our knowledge, our study is the first to report the antitumor effect and working mechanism of GANT61 through down-regulation of STAT3 and SOCS3 in T cell lymphoma cells. This evidence concerns the gene SOCS3 and T-cell non-Hodgkin lymphoma.